- Home
- VTVT vs VERU Comparison
VTVT vs VERU Comparison
Compare VTVT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- VERU
- Stock Information
- Founded
- VTVT 2015
- VERU 1971
- Country
- VTVT United States
- VERU United States
- Employees
- VTVT N/A
- VERU N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- VERU Health Care
- Exchange
- VTVT Nasdaq
- VERU Nasdaq
- Market Cap
- VTVT 54.4M
- VERU 54.6M
- IPO Year
- VTVT 2015
- VERU 1990
- Fundamental
- Price
- VTVT $20.89
- VERU $3.75
- Analyst Decision
- VTVT Strong Buy
- VERU Strong Buy
- Analyst Count
- VTVT 2
- VERU 3
- Target Price
- VTVT $35.50
- VERU $33.33
- AVG Volume (30 Days)
- VTVT 4.2K
- VERU 139.0K
- Earning Date
- VTVT 11-12-2025
- VERU 12-15-2025
- Dividend Yield
- VTVT N/A
- VERU N/A
- EPS Growth
- VTVT N/A
- VERU N/A
- EPS
- VTVT N/A
- VERU N/A
- Revenue
- VTVT $17,000.00
- VERU $16,886,419.00
- Revenue This Year
- VTVT N/A
- VERU N/A
- Revenue Next Year
- VTVT N/A
- VERU N/A
- P/E Ratio
- VTVT N/A
- VERU N/A
- Revenue Growth
- VTVT N/A
- VERU 337.24
- 52 Week Low
- VTVT $12.62
- VERU $2.64
- 52 Week High
- VTVT $26.99
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- VTVT 48.86
- VERU 47.71
- Support Level
- VTVT $20.19
- VERU $3.61
- Resistance Level
- VTVT $21.20
- VERU $3.99
- Average True Range (ATR)
- VTVT 0.97
- VERU 0.30
- MACD
- VTVT -0.30
- VERU -0.10
- Stochastic Oscillator
- VTVT 33.54
- VERU 14.52
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.